Radiolabeled bombesin analogs

Rosalba Mansi, Berthold A. Nock, Simone U. Dalm, Martijn B. Busstra, Wytske M. van Weerden, Theodosia Maina*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

38 Citations (Scopus)
71 Downloads (Pure)


The gastrin‐releasing peptide receptor (GRPR) is expressed in high numbers in a variety of human tumors, including the frequently occurring prostate and breast cancers, and therefore provides the rationale for directing diagnostic or therapeutic radionuclides on cancer lesions after administration of anti‐GRPR peptide analogs. This concept has been initially explored with analogs of the frog 14‐peptide bombesin, suitably modified at the N‐terminus with a number of radiometal chelates. Radiotracers that were selected for clinical testing revealed inherent problems associated with these GRPR agonists, related to low metabolic stability, unfavorable abdominal accumulation, and adverse effects. A shift toward GRPR antagonists soon followed, with safer analogs becoming available, whereby, metabolic stability and background clearance issues were gradually improved. Clinical testing of three main major antagonist types led to promising outcomes, but at the same time brought to light several limitations of this concept, partly related to the variation of GRPR expression levels across cancer types, stages, previous treatments, and other factors. Currently, these parameters are being rigorously addressed by cell biologists, chemists, nuclear medicine physicians, and other discipline practitioners in a common effort to make available more effective and safe state‐of‐the‐art molecular tools to combat GRPR‐positive tumors. In the present review, we present the background, current status, and future perspectives of this endeavor.

This article belongs to the Special Issue Radiopharmaceuticals for Oncological Diseases

Original languageEnglish
Article number5766
Issue number22
Publication statusPublished - 1 Nov 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.


Dive into the research topics of 'Radiolabeled bombesin analogs'. Together they form a unique fingerprint.

Cite this